SCHEMBL4157478

SCHEMBL4157478

Oc1ccc(/C=C2/c3ccccc3CCc3c(Cl)cccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 8/20 0.50
MAOB P27338 4/20 0.41
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
NR3C2 P08235 1/20 0.39
AR P10275 1/20 0.39
RET P07949 1/20 0.39
FLT3 P36888 1/20 0.39
PLK4 O00444 1/20 0.39
PDGFRB P09619 1/20 0.39
PLK1 P53350 1/20 0.39
CYP19A1 P11511 2/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
CYP26A1 O43174 2/20 0.38
EP300 Q09472 1/20 0.36
MEN1 O00255 1/20 0.36
ACHE P22303 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4157481 1.00 MIF (0.50) MIFMAOBNR3C1PGRNR3C2
SCHEMBL8348795 0.87 MIF (0.54) MIFMAOBNR3C1PGRNR3C2
SCHEMBL4174100 0.87 MIF (0.54) MIFMAOBNR3C1PGRNR3C2
SCHEMBL4174103 0.87 MIF (0.54) MIFMAOBNR3C1PGRNR3C2
SCHEMBL8353331 0.86 AR (0.42) MIFMAOBNR3C1PGRNR3C2
SCHEMBL4175622 0.86 AR (0.42) MIFMAOBNR3C1PGRNR3C2
SCHEMBL4175625 0.86 AR (0.42) MIFMAOBNR3C1PGRNR3C2
SCHEMBL6239187 0.85 MIF (0.64) MIFMAOBNR3C1PGRNR3C2
SCHEMBL4170410 0.81 MIF (0.56) MIFMAOBCYP19A1CYP26A1
SCHEMBL4170407 0.81 MIF (0.56) MIFMAOBCYP19A1CYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 MIF 1642/4885MAOB 2154/4885NR3C1 3/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 MIF 1592/4885MAOB 2012/4885NR3C1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.